Evidence map›Paper›PMID 42162150›Full record

ArticleScientific reports2026

Comparative molecular dynamics mapping of metallocarboxypeptidase-peptide interfaces reveals potential hotspots that inspire novel inhibitor design.

Amirhossein Akbarpour Arsanjani, Davood Rabiei Faradonbeh, Ziba Veisi Malekshahi, Babak Negahdari

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Amirhossein Akbarpour ArsanjaniDepartment of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Davood Rabiei FaradonbehBrain and Spinal Cord Injury Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
Ziba Veisi MalekshahiDepartment of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran. ziba.malekshahi@gmail.com.
Babak NegahdariDepartment of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran. b-negahdari@sina.tums.ac.ir.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metallocarboxypeptidases (MCPs) are critical zinc-containing exopeptidases and promising therapeutic targets for conditions ranging from thromboembolic disorders to cancer. Despite their importance, the dynamic determinants governing subfamily-specific peptide recognition remain incompletely understood. In this study, we performed 200 ns molecular dynamics simulations on five distinct A/B MCP-peptide complexes and integrated contact analysis and per-residue energy decomposition (MM/PBSA) to systematically map their interaction profiles. We identified a core set of Grade A and B conserved hotspots-specifically Arg71, Arg127, Glu163, Thr164, and Tyr248-that mediate persistent interactions across the subfamilies. Based on their energetic and geometric profiles, we categorized these residues into three functional classes. Class I (functional hotspots): Such as Arg71 and Arg127, which act as near-permanent "anchoring hubs" with contact occupancies exceeding 90% and dominant negative binding free energies. Class II (topological hotspots): Such as Glu163, which maintains the structural integrity of the active site cleft. Class III (auxiliary energetic contributors): Which provide additional stabilization through transient or non-polar contacts. Furthermore, we identified complex-specific residues, such as Glu270 in hCPB1, that serve as selectivity filters. Collectively, this study highlights the key enzyme residues that mediate persistent interactions at the interface and provides molecular insights that may guide the rational design of novel metallocarboxypeptidase inhibitors.

Indexed as

CarboxypeptidasesMolecular Dynamics SimulationPeptidesBinding SitesCatalytic DomainDrug DesignProtein BindingCarboxypeptidasesPeptidesCarboxypeptidase inhibitorEnzyme–peptide interfaceHydrogen bondMD simulationMetallocarboxypeptidase

Identifiers

PMID42162150
PMCPMC13388685

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.